Sinphar Pharmaceutical Co.,Ltd.

TWSE:1734 Stock Report

Market Cap: NT$6.4b

Sinphar PharmaceuticalLtd Balance Sheet Health

Financial Health criteria checks 5/6

Sinphar PharmaceuticalLtd has a total shareholder equity of NT$3.5B and total debt of NT$1.9B, which brings its debt-to-equity ratio to 54.9%. Its total assets and total liabilities are NT$6.3B and NT$2.8B respectively. Sinphar PharmaceuticalLtd's EBIT is NT$274.4M making its interest coverage ratio 13. It has cash and short-term investments of NT$1.0B.

Key information

54.9%

Debt to equity ratio

NT$1.93b

Debt

Interest coverage ratio13x
CashNT$1.03b
EquityNT$3.52b
Total liabilitiesNT$2.82b
Total assetsNT$6.34b

Recent financial health updates

Recent updates

Impressive Earnings May Not Tell The Whole Story For Sinphar PharmaceuticalLtd (TWSE:1734)

Apr 02
Impressive Earnings May Not Tell The Whole Story For Sinphar PharmaceuticalLtd (TWSE:1734)

Would Sinphar PharmaceuticalLtd (TPE:1734) Be Better Off With Less Debt?

Feb 15
Would Sinphar PharmaceuticalLtd (TPE:1734) Be Better Off With Less Debt?

Can You Imagine How Sinphar PharmaceuticalLtd's (TPE:1734) Shareholders Feel About The 52% Share Price Increase?

Dec 22
Can You Imagine How Sinphar PharmaceuticalLtd's (TPE:1734) Shareholders Feel About The 52% Share Price Increase?

Financial Position Analysis

Short Term Liabilities: 1734's short term assets (NT$2.6B) exceed its short term liabilities (NT$1.2B).

Long Term Liabilities: 1734's short term assets (NT$2.6B) exceed its long term liabilities (NT$1.6B).


Debt to Equity History and Analysis

Debt Level: 1734's net debt to equity ratio (25.7%) is considered satisfactory.

Reducing Debt: 1734's debt to equity ratio has increased from 51.5% to 54.9% over the past 5 years.

Debt Coverage: 1734's debt is well covered by operating cash flow (21.9%).

Interest Coverage: 1734's interest payments on its debt are well covered by EBIT (13x coverage).


Balance Sheet


Discover healthy companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.